Summary of Study ST000414
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000323. The data can be accessed directly via it's Project DOI: 10.21228/M8ZS3N This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000414 |
| Study Title | Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action |
| Study Type | Drug incubation |
| Study Summary | Measuring the impact of MMV Malaria Box compounds on metabolism in Plasmodium falciparum-infected red blood cells |
| Institute | Monash Institute of Pharmaceutical Sciences |
| Department | Drug delivery, disposition and dynamics |
| Laboratory | Creek lab |
| Last Name | Creek |
| First Name | Darren |
| Address | 381 Royal Parade, Parkville, Melbourne, VIC3052, Australia |
| Darren.Creek@monash.edu | |
| Phone | N/A |
| Submit Date | 2016-06-16 |
| Num Groups | 126 |
| Total Subjects | 18 |
| Study Comments | 524 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2017-07-10 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR000449 |
| Treatment Summary: | Cultures (200 µL) were incubated with test compounds (1 µM) for 5 hours in 96-well plates. Four replicate incubations of each compound were conducted and analyzed. Untreated controls contained equivalent amounts of DMSO (as vehicle), and additional ‘quench test’ controls were prepared whereby the test compounds were added after the quenching step, to allow detection of test compound-derived LC-MS features that did not arise from biochemical metabolism within the cells. Each plate contained 10 or 20 test compounds in addition to positive controls (artemisinin and/or atovaquone) and negative controls (untreated DMSO and ‘quench test’ described above). Incubations and extractions for the 100 test compounds (10 compounds with known antimalarial activity and 90 of the highest priority compounds from the Malaria Box including all of plate A and the first row of plate B) were performed in three separate batches, with the known antimalarial compounds and first 10 Malaria Box compounds in the first batch, the next 40 Malaria Box compounds in the second batch, and the following 40 Malaria Box compounds in the third batch. |
| Treatment Compound: | Antimalarials and MMV Malaria Box compounds |
| Treatment Dose: | 1 micromolar |
| Treatment Doseduration: | 5 hours |
| Treatment Vehicle: | DMSO |
| Cell Growth Container: | 96-well V-bottomed plate |
| Cell Media: | RPMI-HEPES |
| Cell Envir Cond: | 37 °C under defined atmosphere (95% N2, 4% CO2, 1% O2) |
| Cell Media Lastchanged: | 18 hours |
